載入中
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
最新資料
US$324.57
−US$2.24 · -0.69%
盤中時間採用ET。市場資料可能有所延遲。
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
盤中時間採用ET。市場資料可能有所延遲。
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3.89億 USD | 2.91億 USD | 5069.9萬 USD | — | — |
| 銷貨成本 | 2877.3萬 USD | 2006.1萬 USD | 309.4萬 USD | — | — |
| 毛利 | 3.6億 USD | 2.7億 USD | 4760.5萬 USD | — | — |
| 研究與開發 | 5804.5萬 USD | 5357.3萬 USD | 4643.1萬 USD | 4246.1萬 USD | 2788.4萬 USD |
| 銷售、一般及管理費用 | 1.47億 USD | 1.14億 USD | 9840.1萬 USD | 7773.5萬 USD | 4039.1萬 USD |
| 營業費用 | 1.99億 USD | 2.05億 USD | 1.57億 USD | 1.45億 USD | 6827.5萬 USD |
| 利息收入 | 2817.6萬 USD | 2966.1萬 USD | 2262.4萬 USD | 522.1萬 USD | 19.7萬 USD |
| 利息支出 | — | — | — | — | 149.2萬 USD |
| 折舊和攤銷 | 655.1萬 USD | 671.4萬 USD | 500.7萬 USD | 405.5萬 USD | 276.9萬 USD |
| 營業利益 | 1.61億 USD | 6569.5萬 USD | −1.1億 USD | −1.45億 USD | −6827.5萬 USD |
| 淨利 | 2.05億 USD | 8915.9萬 USD | 1093.2萬 USD | −1.4億 USD | −6957萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$395.2
上漲空間 21.76%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3.2億0.01%2.3兆 USD0.03%US$381.03-0.40%
Vanguard Morningstar Small-Cap ETFVB2.32億0.12%1853億 USD0.03%US$286.98-1.41%
iShares Russell 2000 ETFIWM2.22億0.28%785.63億 USD0.19%US$277.7-1.29%
State Street SPDR S&P Biotech ETFXBI1.45億1.41%100.75億 USD0.35%US$150.23-0.44%
Vanguard Morningstar Small-Cap Growth ETFVBK1.33億0.29%447億 USD0.05%US$342.24-1.50%
Vanguard Extended Market ETFVXF1.1億0.11%954億 USD0.05%US$233.49-1.56%
Invesco S&P MidCap Momentum ETFXMMO8771.81萬1.21%72.53億 USD0.34%US$148.32-2.25%
iShares Russell 2000 Growth ETFIWO8009.85萬0.56%142.49億 USD0.24%US$355.37-1.43%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFInvesco S&P MidCap Momentum ETFXMMOiShares Russell 2000 Growth ETFIWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
